The objective was to evaluate the relative efficacy of cryoablation (CRYO) versus external beam radiation (EBRT) for clinically locally advanced prostate cancer in a randomized clinical trial. Patients with histologically proven, clinically staged as T2C, T3A or T3B disease were randomized with 6 months of perioperative hormone therapy to one of the two procedures. Owing largely to a shift in practice to longer term adjuvant hormonal therapy and higher doses of radiation for T3 disease, only 64 out of the planned 150 patients were accrued. Twenty-one of 33 (64%) in the CRYO group and 14 of 31 (45%) in the EBRT-treated group who had met the ASTRO definition of failure were also classified as treatment failure. The mean biochemical disease-free survival (bDFS) was 41 months for the EBRT group compared to 28 months for the CRYO group. The 4-year bDFS for EBRT and CRYO groups were 47 and 13%, respectively. Disease-specific survival (DSS) and overall survival (OS) for both groups were very similar. Serious complications were uncommon in either group. EBRT patients exhibited gastrointestinal (GI) adverse effects more frequently. Taking into account the relative deficiency in numbers and the original trial design, this prospective randomized trial indicated that the results of CRYO were less favorable compared to those of EBRT, and was suboptimal primary therapy in locally advanced prostate cancer.
Introduction
Cryoablation (CRYO) of the prostate was first introduced in the 1960s but was quickly abandoned owing to an unacceptably high complication rate. 1, 2 It was reintroduced in 1998 by Onik et al., 3 primarily due to improvements in percutaneous and cryogenic instrumentation and popularization of transrectal ultrasonography as a diagnostic technique of the prostate which allowed monitoring of the freezing process in real time.Because of its minimally invasive nature, with the theoretical advantages of being able to freeze beyond the anatomic prostate and the ability to kill cells regardless of the endocrine response status, the procedure gained popularity for T1 and T2 disease and there was a tremendous proliferation of cryosurgery units in the United States. Onik et al. 3 reported their experience on primary CRYO with short-term biochemical control of 80-90%, and 85% of patients had no morbidity. Other institutions followed with similar reports on small case series on primary CRYO for T1/T2 prostate cancers. For primary CRYO on clinical T3 and T4 disease, data were more scanty. 4, 5 Miller et al. 5 reported on a negative biopsy rate of 95% at 3 months but the mean prostate-specific antigen (PSA) nadir did not reach an undetectable level (0.59 ng/ml). Thus, although early results indicated reasonably effective short-term PSA control and low morbidity for primary CRYO, especially in lower-staged tumors, there were no randomized studies with higher level evidence to support this new technology. A multicentered trial was planned but unfortunately did not materialize. Hence, in the mid-1990s, CRYO was a rapidly proliferating technology without proper validation and the indications for the procedure had not been fully delineated.
Patients and methods
At our institution, we limited CRYO to the salvage situation in radiation failure patients. We also felt that for locally advanced prostate cancer, where radical prostatectomy was not an ideal treatment option, CRYO might be reasonable. Although results were suboptimal, the standard of care for this patient population at the time was short-term neoadjuvant hormone therapy (3 months) before external beam radiotherapy (EBRT). [6] [7] [8] The objective of this study was to evaluate the relative efficacy of CRYO versus EBRT for the clinical T2C/T3 disease in a randomized clinical trial. As the planning for this trial pre-dated the publication by Bolla et al. 9 reporting the benefits of longer term adjuvant hormone therapy in radiotherapy-treated patients with high risk disease, we felt 3 months of neoadjuvant hormone therapy for downsizing the cancer plus 3 months of adjuvant hormone therapy following either CRYO or radiotherapy was reasonable. 10 The schema of this randomized trial is shown in Figure 1 . The investigative protocol received approval from the Local Ethics Review Board and all standard procedures of randomized clinical trial were followed.
Eligibility inclusion criteria
Patients with histologically proven prostate cancer, clinically staged as T2C, T3A or T3B based on digital rectal examination and/or transrectal ultrasound findings, were deemed eligible. Other prerequisites included negative computerized tomography (CT) of the abdomen and pelvis, negative bone scan and serum PSA less than 25 ng/ml. If PSA was greater than 25 ng/ml or CT scan indicated suspicious lymphadenopathy, histologically confirmed negative pelvic nodes had to be established either with percutaneous needle biopsy or pelvic node dissection (open or laparoscopic).
Exclusion criteria
Patients with node-positive disease and distant metastases, prior pelvic radiotherapy or hormone therapy, prostate volume exceeding 75 ml or American Society of Anesthesiology Risk Class43, were ineligible.
Hypotheses (a) CRYO may be a more effective treatment than EBRT for locally advanced prostate cancer; and (b) CRYO has an acceptable morbidity and safety profile.
Study end points
The end point as indicators of patient outcome were (a) local recurrence rate on biopsy; (b) biochemical diseasefree survival (bDFS); (c) disease-specific survival (DSS); (d) overall survival (OS); and (e) complications and adverse effects of both treatment modalities.
Sample size calculations
We estimated the positive biopsy rate at 2 years for these locally advanced prostate cancer patients treated with EBRT to be approximately 40% and for the CRYO group, it was approximately 20%. To detect such a difference of 20% (power of 80%), and significant a-level of 0.05, and allowing for a 10% drop-out rate, we calculated a total of 150 patients needed to be randomized into either one of the two treatment arms.
Statistical calculations
Positive biopsy rates were compared using Fisher's exact test. bDFS, DSS and OS were compared using KaplanMeier curve analysis.
CRYO procedure
The CRYO procedure was performed under general or spinal anesthesia using transrectal ultrasound-guided probe placement. The Cryocare System (Endocare Inc., Irvine, CA, USA) was used. Details of the cryosurgery methodology have been reported previously. [11] [12] [13] Briefly, proper probe placement was confirmed on three-dimensional ultrasound in terms of inter-probe distances, probe orientation and depth of insertion. In most cases, five cryoprobes (range 2-8) were used and two freezethaw cycles were administered with the urethra protected by a urethra-warming device (Cook Urologic Inc., Spencer, IN, USA). Temperature monitoring was achieved with three thermocouples inserted into the Randomized trial of cryoablation versus radiotherapy for T3 prostate cancer JL Chin et al peri-prostatic area (left and right neurovascular bundle regions, and midline near apex).
EBRT
The EBRT protocol employed in 1995 consisted of 66 Gy in 33 fractions, administered at 2 Gy per day, 5 days a week for 6.5 weeks, directed at the prostate, seminal vesicles, and peri-prostatic region. Simulation was performed with a CT-based simulator and the voltage radiotherapy equipment with photon energy of at least 10 ME was used. An isocentric four-field technique was used at planning target volume conformed to the gross tumor volume as indicated by CT imaging plus a 1-cm margin to account for subclinical extraprostatic tumor extension and variability in treatment setup and internal organ motion.
Hormonal therapy
Six months of hormonal therapy with LHRH agonists (Goserelin) was administered starting 3 months before the date of cryosurgery or start of the radiotherapy sessions.
Post treatment monitoring
Serum PSA levels were taken at 1, 3, 6, 12, 18 and 24 months after treatment. For the CRYO group, transrectal ultrasound-guided biopsy was planned at 3, 6, 18 and 24 months post CRYO. For the EBRT group, transrectal ultrasound-guided biopsy was scheduled at 18 and 24 months post treatment. All patients with positive biopsies were given the option to crossover to the other treatment modality. The cryosurgery patients were actually given the opportunity to have a repeat CRYO procedure first if the 3-or 6-month biopsy was positive, before being classified as 'treatment failure' and given the crossover option to EBRT.
Definition of biochemical failure
Two definitions were used for biochemical failure: the American Society for Therapeutic Radiology and Oncology ('ASTRO') definition of three consecutive increases in the serum PSA following nadir; 14 and an alternative definition of the serum PSA reaching 2 ng/ml above the nadir ('Houston þ 2' definition). 15 
Results
In the mean follow-up with 37 months, disappointingly, only 64 out of the planned 150 patients were accrued. The main reason was a shift in practice to longer term adjuvant hormonal therapy and higher doses of radiation for this patient population, as supported by the reports on improved DSS and OS. 9, 16 Other contributing factors to the slow accrual included the failure of a second institution, originally planning to participate in the trial, to establish their cryosurgery program and the general decline in the proportion of patients presenting with advanced prostate cancer. The patient characteristics of the two cohorts (EBRT (n ¼ 31), CRYO (n ¼ 33)) are listed in Table 1 .
With a mean follow-up of 37 months, 21 of 33 (64%) of the CRYO group had met the ASTRO definition of biochemical failure and 14 of 31 (45%) of the radiotherapy-treated group were also classified as treatment failure. Seven CRYO patients and four EBRT patients had a positive biopsy. DSS and OS for both the CRYO and EBRT groups were very similar. The mean bDFS was more favorable for the EBRT group compared to the CRYO group (41 versus 28 months). The 4-year bDFS for EBRT and CRYO groups were 47 and 13%, respectively (see Table 2 ). The Kaplan-Meier survival curves in Figure 2 show the bDFS for the EBRT group compared to the CRYO group, using both definitions of biochemical failure: the ASTRO definition (P ¼ 0.0277; Figure 2a ) and the alternative 'Houston þ 2' definition ( Figure 2b ; P ¼ 0.0123).
Overall, six patients have died, two from prostate cancer (one each from the CRYO and EBRT arms) and four from unrelated causes.
Serious complications were uncommon in either group. For the EBRT, bloody diarrhea (one patient) and perforated cecum (one patient) were the notable serious adverse events. CRYO resulted in one patient each who suffered, respectively, from acute urinary retention, cerebrovascular accident and severe constipation requiring hospitalization. Anticipated adverse effects were divided into gastrointestinal (GI), genitourinary (GU) and hormonal effects (Table 3a) . Detailed complaints from each domain are listed in Tables 3b and 3c . As expected, the EBRT group exhibited GI adverse effects more frequently, compared to the CRYO group. Urinary complaints and adverse events of the hormone therapy were equally prevalent in both groups. Randomized trial of cryoablation versus radiotherapy for T3 prostate cancer JL Chin et al
Discussion
This randomized trial was designed to compare the utility of CRYO and EBRT in locally advanced prostate cancer. The different post-treatment biopsy schedule was designed with the different therapeutic mechanisms and timeframes of the two modalities in mind, being cognizant of the fact that more frequent biopsies in the CRYO arm might result in detection of more positive biopsies in that arm. However, biopsy within 1 year following external radiotherapy would have resulted in some equivocal and possibly erroneous histologic interpretations leading to premature intervention on the EBRT patients. Conversely, a less frequent and less intensive post-operative biopsy schedule for the CRYO group (for example, first biopsy at 24 months) would result in CRYO failures being undetected for an unacceptable (and unethical) time period. The trial met with unexpected events that seriously compromised the patient's accrual efforts. What was considered standard therapy for locally advanced prostate cancer in 1995 when the trial was conceived, that is short-term neoadjuvant hormone therapy and EBRT at a dosage of 65-68 Gy, became sub-optimal therapy during the course of patient accrual for this trial. With the improved DSS and OS reported by Bolla et al. employing long-term adjuvant hormonal therapy and the trend towards higher EBRT dose intensity becoming the standard, 9, 16 accruing patients to this trial with the lower dose intensity and short-term hormone therapy was no longer considered ethical or practical. Modifying the eligibility criteria to include lower-staged disease, altering the radiation techniques and dosages, or increasing the length of adjuvant hormone therapy partway through the accrual period would have rendered the trial results uninterpretable and invalid. Another important consideration was the generally observed trend of lower proportion of patients presenting with advanced disease. Thus the trial was terminated with fewer than half of the target accrual. Nevertheless, this still represents the first reported randomized trial between CRYO for prostate cancer and another 'standard' treatment modality. Keeping in mind the small number of patients in each arm, the results were still noteworthy and seemed to refute our initial hypothesis that CRYO would result in lower positive biopsy rate and lower rate of biochemical recurrence. The results indicated a trend towards a less favorable bDFS for the CRYO group compared to the EBRT group and at 4 years, the bDFS The positive biopsy rate of 20% is proportionate with results of other CRYO series (13-38%), including our own on salvage CRYO, although none of the other series had exclusively locally advanced disease. 13 Prepelica et al.
17 recently reported on their experience on primary CRYO on 65 'high risk' patients (PSA410 or Gleason scoreX8). One out of eight post-cryosurgery biopsies (12.5%) was positive. Arguably, many of these patients were not classified as locally advanced at the time of CRYO, although they would have had significant potential for local progression. Several other nonrandomized series on CRYO for 'all comers' suggested a 'role for CRYO in the management of localized prostate cancer'. [18] [19] [20] [21] These series typically included 12-20% patients with higher-staged tumors (T2B-T4), although the data on more locally extensive cancers were difficult to interpret as some parameters were not controlled. These include the presence or absence or length of hormone therapy, subjective designation of local 'T staging', separate reporting on results for various 'risk categories' rather than 'stages' and combined reporting on both primary and salvage cases. Thus, conclusion on the utility of primary CRYO on more locally extensive disease cannot be drawn from these studies.
Except for the bDFS trend, the DSS and OS for our two groups were identical, although longer follow-up may prove otherwise. The poorer results of CRYO for locally advanced prostate cancer confirm the inadequacy of local single-modality CRYO, in the face of bulky local disease, and underscore the importance of adequate neoadjuvant and adjuvant hormone therapy. One main reason for treatment failure in these poor risk patients is likely to be the presence of occult distant metastatic disease.
In terms of adverse effects, as expected, EBRT resulted in a higher incidence of GI problems. Approximately one-third of patients with CRYO reported mild to moderate perineal and genital pain, although it was transient and none was debilitating. CRYO as primary therapy in this setting resulted in a low incidence of other GU or GI problems, confirming its safety in this setting.
Conclusion
This prospective randomized trial on CRYO versus EBRT for T2C-T3B prostate cancer, taking into account the relative deficiency in numbers and the original trial design, indicates that CRYO is the suboptimal primary therapy in locally extensive prostate cancer. This conclusion, however, should not be extrapolated to lessadvanced cancers where acceptable intermediate-term results from CRYO have recently been reported from other nonrandomized series. [18] [19] [20] [21] Definitive evidence from other randomized trials on the efficacy of CRYO for lower-staged prostate cancer is still pending.
